Improving endocrine therapy for breast cancer: It's not that simple

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 171-173

  Dees, E Claire ^a   Carey, Lisa A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN; TEMSIROLIMUS;

ADJUVANT THERAPY; ANOREXIA; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENZYME METABOLISM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHARMACOGENOMICS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; STOMATITIS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84872593587     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2655     Document Type: Review

References (25)

1. Johnston SR, Martin LA, Head J, et al: Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 95:173-181, 2005 (Pubitemid 41137308)
2. Johnston SRD: New strategies in estrogen receptor-positive breast cancer. Clinical Cancer Res 16:1979-1987, 2010
3. Network CGA: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
4. Clark AS, West K, Streicher S, et al: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717, 2002
5. Miller T, Fox E, Gonzalez-Angulo A, et al: Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is dependent upon phosphatidylinositol-3 kinase (PI3K) signaling. Cancer Res 69:24, 2009 (suppl)
6. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059-8067, 2004 (Pubitemid 39587547)
7. Sanchez CG, Ma CX, Crowder RJ, et al: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13:R21, 2011
8. O'Brien KM, Cole SR, Tse CK, et al: Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100-6110, 2010
9. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
10. Piccart-Gebhart MJ, Noguchi S, Pritchard KI, et al: Everolimus for postmenopausal women with advanced breast cancer: Updated results of Bolero-2 phase III trial. J Clin Oncol 30:21s, 2012 (suppl; abstr 559)
11. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 30:2718-2724, 2012
12. Chulikavit M, Casciano R, Stern L, et al: Cost of treating patients with advanced renal cell carcinoma with everolimus versus temsirolimus after failure on sunitinib or sorafenib. 2010 Genitourinary Cancers Symposium, San Francisco, CA, March 5-7, 2010
13. Wolff AC, Lazar AA, Bondarenko I, et al: Randomized phase III placebocontrolled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195-202, 2013
14. Rugo HS, Burris HA III, Gnant M, et al: Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. J Clin Oncol 30, 2012 (abstr 104)
15. Baselga J, Semiglazov V, van Dam P, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637, 2009
16. Anglicheau D, Legendre C, Beaune P, et al: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update. Pharmacogenomics 8:835-849, 2007 (Pubitemid 47288980)
17. Juric D, Baselga J: Tumor genetic testing for patient selection in phase I clinical trials: The case of PI3K inhibitors. J Clin Oncol 30:765-766, 2012
18. Rini BI: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clinical Cancer Res 14:1286-1290, 2008 (Pubitemid 351413905)
19. Sanchez-Fructuoso AI: Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 4:807-819, 2008 (Pubitemid 352003202)
20. Zagouri F, Sergentanis TN, Chrysikos D, et al: MTOR inhibitors in breast cancer: A systematic review. Gynecol Oncol 127:662-672, 2012
21. Johnston SR: Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9:S28-S36, 2009 (suppl 1)
22. Osborne CK, Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-247, 2011
23. Mehta RS, Barlow WE, Albain KS, et al: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435-444, 2012
24. Bergh J, Jonsson PE, Lidbrink EK, et al: FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919-1925, 2012
25. Ellis MJ, Gao F, Dehdashti F, et al: Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302:774-780, 2009